Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481209 | 0.93 | KMT2A (0.47) | KMT2APOLBTDP1MALT1SMN1; SMN2 | |
| SCHEMBL1305598 | 0.89 | KMT2A (0.53) | KMT2APOLBTDP1MALT1MEN1 | |
| SCHEMBL4394146 | 0.85 | KMT2A (0.52) | KMT2APOLBTDP1MALT1SMN1; SMN2 | |
| SCHEMBL4398015 | 0.84 | KMT2A (0.50) | KMT2APOLBTDP1MALT1SMN1; SMN2 | |
| SCHEMBL4468454 | 0.83 | KMT2A (0.46) | KMT2ASMN1; SMN2RAB9AMEN1TSHR | |
| SCHEMBL13373170 | 0.82 | KMT2A (0.47) | KMT2APOLBTDP1MALT1SMN1; SMN2 | |
| SCHEMBL7323646 | 0.80 | KMT2A (0.44) | KMT2APOLBTDP1MALT1SMN1; SMN2 | |
| SCHEMBL8367257 | 0.79 | RAB9A (0.51) | KMT2APOLBTDP1MALT1SMN1; SMN2 | |
| SCHEMBL13123494 | 0.79 | KMT2A (0.48) | KMT2APOLBTDP1MALT1SMN1; SMN2 | |
| SCHEMBL5424673 | 0.79 | PIK3CD (0.54) | KMT2APOLBTDP1MALT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | claimed |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | claimed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | claimed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | claimed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | claimed |
| US-6855719-B1 | Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives | ASTRAZENECA AB (SE) | 2005-02-15 | — | — | US | claimed |
| US-20040063773-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2004-04-01 | — | — | US | claimed |
| EP-1214318-B1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-08 | — | — | EP | claimed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | claimed |
| EP-1214318-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | claimed |
| WO-2001014375-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-01 | — | — | WO | claimed |
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2019-05-09 | — | — | US | disclosed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| US-9452994-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-6291505-B1 | PYRAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-09-18 | — | — | US | disclosed |
| US-6262098-B1 | ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-1102753-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2001014375-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000007996-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | KMT2A 2325/4885POLB 1912/4885TDP1 1814/4885 |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | KMT2A 1471/4885POLB 2640/4885TDP1 508/4885 |
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | PIK3CA, PIK3CD, PIK3R5 | KMT2A 1554/4885POLB 1988/4885TDP1 1739/4885 |
| US-20040063773-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | KMT2A 2242/4885POLB 1869/4885TDP1 1009/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | KMT2A 2242/4885POLB 1869/4885TDP1 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.